Nuvation Bio Inc. (NUVB) has a MoatMap StockRank of 16/100 based on Quality (36/100), Value (36/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL. Nuvation Bio is an oncology-focused biotech company. Despite some promising pipeline candidates, it lacks commercial revenues and predictable owner earnings.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing a proprietary pipeline of novel, targeted oncology therapies to address significant unmet needs in cancer care. The company's competitive moat is built on its advanced drug discovery engine, which targets key oncogenic drivers and resistance mechanisms, highlighted by its lead candidate taletrectinib, a potential best-in-class ROS1 inhibitor. Led by an experienced management team with a track record of successful oncology drug development, Nuvation Bio is well-positioned to advance its deep pipeline of small molecule candidates.
| Price | $4.93 |
| Market Cap | $1.7B |
| P/E (Forward) | -86.17 |
| Price/Book | 5.63 |
| Return on Equity | -39.5% |
| Return on Invested Capital | -37.3% |
| Debt/Equity | 67.90 |
| Gross Margin | 90.8% |
| Operating Margin | 4.7% |
| Revenue Growth | 2598.7% |
| Free Cash Flow | $-100M |
Nuvation Bio Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).